Table 3.
Investigator-assessed tumor response rate by Response Evaluation Criteria in Solid Tumors version 1.1.
| n (%) | Fianlimab monotherapy (n = 31) | Fianlimab + cemiplimab (n = 47) | Monotherapy to combinationa (n = 16) |
|---|---|---|---|
| Objective response rate | 0 | 2 (4.3) | 3 (18.8) |
| Best overall response | |||
| Complete response | 0 | 0 | 0 |
| Partial response | 0 | 2 (4.3) | 3 (18.8) |
| Stable disease | 13 (41.9) | 12 (25.5) | 6 (37.5) |
| Progressive disease | 10 (32.3) | 26 (55.3) | 4 (25.0) |
| Not evaluated | 8 (25.8) | 7 (14.9) | 3 (18.8) |
| Disease control rate | 13 (41.9) | 14 (29.8) | 9 (56.3) |
a
A subset of patients who received fianlimab monotherapy as primary treatment, then subsequently received fianlimab-plus-cemiplimab combination therapy during a re-treatment phase. Data presented were gathered from the period during which patients were receiving combination therapy.